ANTX
AN2 Therapeutics Inc
NASDAQ: ANTX · HEALTHCARE · BIOTECHNOLOGY
$4.68
-1.27% today
Updated 2026-04-29
Market cap
$163.78M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.16
Dividend yield
—
52W range
$1 – $7
Volume
1.7M
AN2 Therapeutics Inc (ANTX) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $-2.49M | $-5.36M | $-20.48M | $-33.46M | $-53.29M | $-49.26M | $-29.83M |
| Capital expenditures | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation | — | — | — | — | — | — | — |
| Stock-based comp | — | $40000.00 | $974000.00 | $4.39M | $8.41M | $8.34M | $6.25M |
| Free cash flow | $-2.49M | $-5.36M | $-20.48M | $-33.46M | $-53.29M | $-49.26M | $-29.83M |
| Investing cash flow | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | $1.82M | — | — | — |
| Share repurchases | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | — | — |